Summary
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms
and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet
counts of 50 x 10^9/L to 100 x 10^9/L. It is anticipated that individualized dose
optimization from the starting ruxolitinib level of 5 mg bid will be associated with
reductions in splenomegaly, MF-associated symptoms and inflammatory cytokine levels.